Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2025-12-26 @ 5:58 AM
Study NCT ID:
NCT04616859
Status:
UNKNOWN
Last Update Posted:
2020-11-09
First Post:
2020-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Binge Drinking of Alcohol Mixed With Energy Drinks
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000428', 'term': 'Alcohol Drinking'}, {'id': 'D003075', 'term': 'Coitus'}], 'ancestors': [{'id': 'D004327', 'term': 'Drinking Behavior'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D012725', 'term': 'Sexual Behavior'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000431', 'term': 'Ethanol'}, {'id': 'D061215', 'term': 'Energy Drinks'}], 'ancestors': [{'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001628', 'term': 'Beverages'}, {'id': 'D000066888', 'term': 'Diet, Food, and Nutrition'}, {'id': 'D010829', 'term': 'Physiological Phenomena'}, {'id': 'D019602', 'term': 'Food and Beverages'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'Double-blind'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 32}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-10-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-11', 'completionDateStruct': {'date': '2021-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-11-05', 'studyFirstSubmitDate': '2020-10-30', 'studyFirstSubmitQcDate': '2020-11-04', 'lastUpdatePostDateStruct': {'date': '2020-11-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-11-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in subjective effects measured with Biphasic alcohol effects scale (BAES)', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Subjective effects of alcohol will be measured using Biphasic alcohol effects scale (0-70 points). Higher scores mean worse outcome. Obtained baseline and 1, 1.30, 2, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in psychomotor vigilance task (PVT)', 'timeFrame': 'From baseline to 6 hours after administration', 'description': 'Test will be performed using a specific software. Mean latency will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.'}], 'secondaryOutcomes': [{'measure': 'Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Calculation of AUC of ethanol blood concentrations. Obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Area under the concentration-time curve (AUC 0-8h) of ethanol breath concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Obtained baseline and 0.15, 0.30 , 0.45, 1, 1.15,1.30, 1.45, 2, 2.15, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Calculation of AUC of caffeine concentrations obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Maximum concentration (Cmax) of ethanol in blood', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Maximum concentration (Cmax) of ethanol in blood'}, {'measure': 'Maximum concentration (Cmax) of caffeine in plasma', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Maximum concentration (Cmax) of caffeine in plasma'}, {'measure': 'Time to reach maximum concentration (tmax) of ethanol in blood', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Time to reach maximum concentration (tmax) of ethanol in blood'}, {'measure': 'Time to reach maximum concentration (tmax) of ethanol in breath air', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Time to reach maximum concentration (tmax) of ethanol in breath air'}, {'measure': 'Time to reach maximum concentration (tmax) of caffeine in plasma', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Time to reach maximum concentration (tmax) of caffeine in plasma'}, {'measure': 'Area under the concentration-time curve (AUC 0-8h) of taurine plasma concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Calculation of AUC of taurine concentrations obtained baseline and 0.30h , 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration'}, {'measure': 'Maximum concentration (Cmax) of taurine plasma concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Maximum concentration (Cmax) of taurine plasma concentrations'}, {'measure': 'Time to reach maximum concentration (tmax) of taurine plasma concentrations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Time to reach maximum concentration (tmax) of taurine plasma concentrations'}, {'measure': 'Change in drunkenness feeling', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Drunkenness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in dizziness feeling', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Dizziness will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in drowsiness feeling', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Drowsiness will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in palpitations reported by the participant', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Palpitations will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in anxiety feeling', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Anxiety will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in headache', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Headache will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in ability and predisposition to drive in certain situations', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Will be measured using a visual analog scale (0-100 mm).Higher scores mean worse outcome. Obtained baseline and 1.30, 4, 6 and 8-h after administration.'}, {'measure': 'Desire to keep drinking', 'timeFrame': 'At 1.30 hours', 'description': 'Will be measured using a visual analog scale (0-100 mm). Higher scores mean worse outcome. Obtained at the end of beverage administration. Only one measure at 1.30 hours.'}, {'measure': 'Change in subjective effects measured with Addiction Research Center Inventory (ARCI)', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Obtained baseline and 1, 1.45, 4, 6 and 8-h after administration.'}, {'measure': 'Change in blood pressure', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Systolic and diastolic blood pressure (mmHg) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in heart rate', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Heart rate (beats/min) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in oral temperature', 'timeFrame': 'From baseline to 8 hours after administration', 'description': 'Oral temperature (ºC) will be measured obtained baseline and 0.30, 1, 1.30, 2, 2.30, 3, 4, 6 and 8-h after administration.'}, {'measure': 'Change in Maddox Wing score (MW)', 'timeFrame': 'From baseline to 6 hours after administration', 'description': 'Maddox wing is a device for the measurement of diopters of horizontal heterophoria. From 22 (exophoria) to 15 (esophoria). Higher scores mean worse outcome.Obtained baseline and 1.30, 4 and 6-h after administration.'}, {'measure': 'Beverage identification', 'timeFrame': '8 hours after administration', 'description': 'Beverage identification questionnaire.There is an option to select each treatment condition. Only measured at 8h after administration'}, {'measure': 'Change in tracking test performance', 'timeFrame': 'From baseline to 6 hours after administration', 'description': 'Test will be performed using a computer program. Total time outside the road and number of errors will be measured. Obtained baseline and 1.30, 4 and 6-h after administration.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['alcohol binge drinking', 'alcohol', 'energy drinks', 'pharmacokinetics', 'caffeine', 'gender'], 'conditions': ['Healthy', 'Alcohol Drinking']}, 'referencesModule': {'references': [{'pmid': '40487410', 'type': 'DERIVED', 'citation': 'Hladun O, Papaseit E, Poyatos L, Martin S, Perez-Acevedo AP, Barriocanal AM, Bustos-Cardona T, Malumbres S, De La Torre R, Langohr K, Farre M, Perez-Mana C. No significant gender differences in driving-related skills following alcohol mixed with energy drinks during an experimental binge-drinking episode. Front Pharmacol. 2025 May 23;16:1581229. doi: 10.3389/fphar.2025.1581229. eCollection 2025.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to assess the relevance of gender in the acute effects (subjective, physiological and driving-related skills) observed after controlled administration of alcohol in a binge-drinking pattern mixed with energy drinks (AmED)', 'detailedDescription': 'Consumption of alcohol mixed with energy drinks (AmED) has increased mainly among young people. Energy drinks (ED) are usually combined with alcohol with the intention of counteracting its effects. However, most studies have not shown a reduction in drunkenness and consumption is related with engagement of risk-taking behaviours like driving under alcohol effects. It is already known that alcohol concentrations and effects are higher in women than in men even after adjusting dose by weight.\n\nThe relevance of gender in the acute effects of alcohol associated with ED consumed in a binge-drinking pattern has been poorly studied. A randomized clinical trial will be conducted in healthy volunteers (1:1) and four treatment conditions will be administered: alcohol+ED, alcohol+placebo of ED, placebo of alcohol+ED and placebo of alcohol+placebo of ED. Subjective and physiological effects, driving related skills, and alcohol and caffeine concentrations will be measured along an 8-hours period. A pilot study has been conducted with the first 6 volunteers to select the alcohol doses. In the definitive study 70 g of alcohol in men and 55 g in women will be used.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '40 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Males and females between 18-40 years old, weight between 50 and 100 kg and BMI (BMI=weight/height²) between 20-28 kg/m². Lower or higher BMIs will be allowed, if the researchers considered that do not suppose a risk to the subjects and do not interfere with the objectives of the study.\n2. Recreational alcohol consumption in form of occasional binge-drinking (≥1 episode / month) and at least consumption of 1 unit (10 g, "standard" drink - one alcoholic drink equivalent) per day or its equivalent over the whole week \\[7 units, 70 g)\\]) and having experienced drunkenness several times\n3. Regular consumption of beverages containing methylxanthines at least 7 per week (coffee, tea, chocolate, cola soda, energy drinks). Consumption of energy drinks at least once.\n4. Understand and accept the study\'s procedures and sign an informed consent form.\n5. No evidence of somatic or psychiatric disorders as per past medical history and physical examination.\n6. The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator\'s opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.\n\nExclusion Criteria:\n\n1. Not fill the inclusion criteria.\n2. Pathological history or evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of drugs or symptoms suggestive of drug-induced gastrointestinal irritation.\n3. Present history of a substance use disorder according to Diagnostic and Statistical Manual for Mental Disorders (DSM-V), except for nicotine. Past history of mild substance use disorder (corresponding to substance abuse according to DSM-IV) could be included.\n4. Previous or actual psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs.\n5. Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks\n6. Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial.\n7. Individuals intolerant or having experienced a severe adverse reaction to alcohol or energy drinks. Asian subjects with no intolerance or no serious adverse reactions to alcohol could be included.\n8. Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators\' opinion, they pose no threat to the subjects and they won\'t interfere with the study\'s objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session.\n9. Smokers of \\>5 cigarettes/day\n10. Consumption of \\>20 g/day of alcohol (females) or of \\>40 g/day (males)\n11. Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study.\n12. Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.\n13. Subjects with positive serology to Hepatitis B, C or HIV.\n14. Pregnant, breastfeeding women and those using hormonal contraception,. Those not using an effective contraceptive (i.e. abstinence, intrauterine devices, barrier methods or partner vasectomy).\n15. Women with amenorrhea or suffering severe premenstrual syndrome.'}, 'identificationModule': {'nctId': 'NCT04616859', 'acronym': 'ENERGYBINGE', 'briefTitle': 'Binge Drinking of Alcohol Mixed With Energy Drinks', 'organization': {'class': 'OTHER', 'fullName': 'Fundació Institut Germans Trias i Pujol'}, 'officialTitle': 'Combination of Alcohol and Energy Drinks in a Binge Drinking Pattern: Acute Effects and Gender Differences', 'orgStudyIdInfo': {'id': 'HUGTP/ENERGYBINGE/PNSD/1'}, 'secondaryIdInfos': [{'id': 'HUGTP/ENERGYBINGE/PNSD/1', 'type': 'OTHER', 'domain': 'Hospital Universitari Germans Trias i Pujol'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Alcohol and Energy Drink (AmED)', 'description': 'The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).\n\nWomen: Ethanol 172 ml (55 g) + ED 589 ml Men: Ethanol 219 ml (70 g) + ED 750 ml', 'interventionNames': ['Dietary Supplement: Alcohol and Energy Drink (AmED)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Alcohol and Energy drink Placebo', 'description': 'The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).\n\nWomen: Ethanol 172 mL (55 g) + placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol 219 mL(70 g) + placebo ED 750 mL (a non-caffeinated soft drink)', 'interventionNames': ['Dietary Supplement: Alcohol and Energy drink Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Alcohol placebo and Energy drink', 'description': 'The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).\n\nWomen: Ethanol placebo (water) 172 mL + ED 589 mL Men: Ethanol placebo (water) 219 mL + ED 750 mL', 'interventionNames': ['Dietary Supplement: Alcohol placebo and Energy drink']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Alcohol placebo and Energy drink placebo', 'description': 'The total volume of drink will be 761 ml in women and 969 ml in men. The doses will be divided into 6 fractions administered one every 15 min simulating a binge drinking pattern (80 min in total).\n\nWomen: Ethanol placebo (water) 172 mL+ placebo ED (a non-caffeinated soft drink) 589 mL Men: Ethanol placebo (water) 219 mL + placebo ED (a non-caffeinated soft drinks) 750 mL', 'interventionNames': ['Dietary Supplement: Alcohol placebo and energy drink placebo']}], 'interventions': [{'name': 'Alcohol and Energy Drink (AmED)', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Multiple oral dose of alcohol mixed with ED', 'armGroupLabels': ['Alcohol and Energy Drink (AmED)']}, {'name': 'Alcohol and Energy drink Placebo', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Multiple oral dose of alcohol mixed with ED placebo (soft drink)', 'armGroupLabels': ['Alcohol and Energy drink Placebo']}, {'name': 'Alcohol placebo and Energy drink', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Multiple oral dose of alcohol placebo (water) mixed with ED', 'armGroupLabels': ['Alcohol placebo and Energy drink']}, {'name': 'Alcohol placebo and energy drink placebo', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)', 'armGroupLabels': ['Alcohol placebo and Energy drink placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08916', 'city': 'Badalona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Clara Pérez-Mañá, MD, PhD', 'role': 'CONTACT', 'email': 'cperezm.mn.ics@gencat.cat', 'phone': '+34 934978865'}, {'name': 'Magi Farré, MD,PhD', 'role': 'CONTACT', 'email': 'mfarre.germanstrias@gencat.cat', 'phone': '+34 934978865'}, {'name': 'Clara Pérez-Mañá, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Magí Farré, MD, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Esther Papaseit, MD, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ana Maria Barriocanal, MD, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Soraya Martin, RN', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alexandra Vila, RN', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Olga Hladun, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ana Pilar Pérez, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Melani Nuñez, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Lourdes Poyatos, BS', 'role': 'SUB_INVESTIGATOR'}], 'facility': "Hospital Universitari Germans Trias i Pujol-Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)", 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}], 'centralContacts': [{'name': 'Clara Pérez-Mañá, MD,PhD', 'role': 'CONTACT', 'email': 'cperezm.mn.ics@gencat.cat', 'phone': '+34 93 497 88 65'}, {'name': 'Magi Farré, MD, PhD', 'role': 'CONTACT', 'email': 'mfarre.germanstrias@gencat.cat', 'phone': '+34 93 497 88 65'}], 'overallOfficials': [{'name': 'Clara Pérez-Mañá, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Universitari Germans Trias i Pujol-IGTP'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fundació Institut Germans Trias i Pujol', 'class': 'OTHER'}, 'collaborators': [{'name': 'Germans Trias i Pujol Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}